BioWorld

April 7, 2003

Administration Won't Reimburse Failed Project BioShield Drugs

Senior Bush administration officials said companies contracted to develop biomedical countermeasures under Project BioShield would not receive full government payment until the FDA approved their products. (BioWorld Today) Read More

For Biotech, Speaker Declares: 'I've Never Seen A Better Time'

Palindromic DNA Sequence Allows p53 Target Genes To Kill Off Cancer Cells & Suppress Tumor Formation

Deltagen Gains At Least $10M In Private Financing Commitment

Correction

Memantine Improves Cognition When Combined With Aricept

Affymetrix Stock Falls Fast As It Projects Lower Product Revenue

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...